Wolfgang Storf

Wolfgang Storf joined AAT Research in 2016 as chief executive officer. Prior to that, he was chief strategy officer with the MS Pharma Group. He was also chief executive of Novartis-Sandoz in South Africa and held other senior management positions with Novartis-Sandoz, Apotex and Johnson & Johnson in different regions of the world. Mr Storf is a seasoned senior executive with proven global strategic and execution leadership experience, covering commercial and technical operations as well R&D responsibility inside multinational and private businesses in the pharmaceutical and medical industry. He has a highly successful record of entering new markets, leading company turnarounds and effectively managing crisis missions. He also has experience in post-merger integration programs in branded/unbranded markets.
Bio last updated 08 Oct 2018

Access to our data for Wolfgang Storf is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Wolfgang Storf is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 28/09/18

1 year TSR5 year TSR
65thAusCann Group Holdings116%61%
705thNeurotech International-46%0%
736thCervantes Corporation-53%19%
809thTech Mpire-73%-18%
739 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Chief Executive Officer, Executive Director
Year started and most recent title


208th↓Cervantes Corporation$76k
209th↓Tech Mpire$73k
210th↓Neurotech International$67k
211th↓AusCann Group Holdings$54k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer